[1]孙玉颖,田 侃.我国生物类似药发展现状及挑战[J].卫生经济研究,2024,41(04):1-3,9.
　SUN Yuying,TIAN Kan.Development Status and Challenges of Biosimilars in China[J].Journal Press of Health Economics Research,2024,41(04):1-3,9.
点击复制

我国生物类似药发展现状及挑战
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年04期
页码:
1-3,9
栏目:
改革探索
出版日期:
2024-03-29

文章信息/Info

Title:
Development Status and Challenges of Biosimilars in China
作者:
孙玉颖1; 田 侃2
1.南京中医药大学卫生经济管理学院，江苏 南京 210023
2.南京中医药大学养老服务与管理学院，江苏 南京 210023
Author(s):
SUN Yuying;  TIAN Kan
School of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210023, China
关键词:
生物类似药; 发展现状; 霍尔三维结构模型
Keywords:
biosimilars;  development status;  Hall three dimensions structure model
分类号:
R95
文献标志码:
A
摘要:
目的：促进生物类似药发展，提高临床用药安全性和经济性。方法：通过文献分析法，了解我国生物类似药的发展现状，并对其生产研发、临床应用和安全监测方面存在的问题进行分析，参考霍尔三维空间结构模型，构建生物类似药管理结构。结果：我国生物类似药发展过程面临本土培养基供应受限、质量相似性难控、医患双方接受度不高、临床循证指南缺失等挑战。结论：分阶段关注生物类似药的发展，前端生产研发中，促进本土培养基企业培育，规范制药企业生产；中端临床应用中，完善临床循证指南，加强医务人员专业教育；末端安全监测中，加强不良反应监测以及对特殊人群的重点监测。
Abstract:
Abstract: Objective To promote the development of biosimilars, and to improve the safety and economy of clinical medication. Methods Through literature analysis, the development status of biosimilars in China was understood, and the problems existing in production and development, clinical application and safety monitoring were analyzed. Referring to the Hall three dimensions structure model, the management structure of biosimilars was constructed. Results In the development process of biosimilars in China, it faced the challenges such as limited local supply of biosimilar culture media, difficult control of quality similarity, low acceptance by both doctors and patients, and lack of clinical evidence-based guidelines. Conclusion Greater attention should be paid to the three stages of time dimension in the spatial structure of biosimilars. It is necessary to promote the cultivation of local culture medium enterprises and standardize the production of pharmaceutical enterprises in the front-end production, research and development, improve the clinical evidence-based guidelines and strengthen the professional education of medical staff in the middle-end clinical application, and strengthen the monitoring of adverse reactions and the key monitoring of special populations in the end-end safety detection.

参考文献/References:

[1] Carver K H,Elikan J,Lietzan E.An unofficial legislative history of the biologics price competition and innovation act of 2009 [J].Food and Drug Law Journal,2010,65(04):671-818.
[2] KOS J.Biological drugs[J].Farmacevtski vestnik，2009,60(02):61-66.
[3] 胡杨，宋再伟，赵荣生.生物类似药临床应用的循证评价及循证指南制定方案[J].中国医院药学杂志，2021，41（21）：2157-2163.
[4] J.H.Lim,et al.A-Mab:a case study in bioprocess development[J].Journal of Industrial and Engineering Chemistry,2018,62(October):471-478.
[5] 林夏，杨克虎，陈耀龙，等.中国临床实践指南的现状与思考[J].中国循证医学杂志，2017，17（05）：497-500.
[6] Kvien T K,Patel K,Strand V.The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems[C].Seminars in Arthritis and Rheumatism.WB Saunders.2022,52:151939.
[7] 胡杨，宋再伟，姜丹，等.抗肿瘤生物类似药临床互换用药有效性与安全性的系统评价[J].中国卫生资源，2022，25（06）：695-700.
[8] 陶千山，董毅，张青，等.R-CHOP序贯H-CHOP治疗弥漫大B细胞淋巴瘤的研究[J].中华保健医学杂志，2020，22（04）：354-356.
[9] 朱昶宇，童荣生.生物类似药在我国的用药管理挑战及对策探讨[J].中国医院药学杂志，2020，40（04）：364-368.
[10] 梅丹，都丽萍，张钰宣.多维度关注生物类似药的管理与临床应用[J].中国药房，2020，31（03）：373-378.
[11] 柳鹏程，王佳域，陈锦敏，等.欧美药物警戒政策研究及对我国的启示[J].中国药物警戒，2020，17（12）：6.

相似文献/References:

[1]陈 宁.辽宁省健康产业发展态势与对策研究[J].卫生经济研究,2017,(04):35.

更新日期/Last Update: 2024-03-29